+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Spinal Muscular Atrophy Treatment Market by Type (Type 1, Type 2, Type 3), Treatment (Drug Therapy, Gene Replacement Therapy), Route of Administration - Cumulative Impact of High Inflation - Forecast 2023-2030

  • PDF Icon

    Report

  • 242 Pages
  • May 2023
  • Region: Global
  • 360iResearch™
  • ID: 4968589
UP TO OFF until Jun 30th 2023
The Global Spinal Muscular Atrophy Treatment Market size was estimated at USD 1,394.26 million in 2022, USD 1,606.81 million in 2023, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 15.38% to reach USD 4,379.52 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Spinal Muscular Atrophy Treatment Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Spinal Muscular Atrophy Treatment Market in order to forecast the revenues and analyze trends in each of following sub-markets:
  • Based on Type, market is studied across Type 1, Type 2, Type 3, and Type 4. The Type 4 is projected to witness significant market share during forecast period.
  • Based on Treatment, market is studied across Drug Therapy and Gene Replacement Therapy. The Gene Replacement Therapy is projected to witness significant market share during forecast period.
  • Based on Route of Administration, market is studied across Intrathecal and Oral. The Intrathecal is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Spinal Muscular Atrophy Treatment Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Spinal Muscular Atrophy Treatment Market, including Astellas Pharma Inc., Biogen Inc., Catalyst Pharmaceuticals, Inc., Cytokinetics, Incorporated, F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Natera Inc., NMD PHARMA A/S, Novartis AG, Novo Nordisk A/S, PerkinElmer, Inc., Pfizer Inc., PTC Therapeutics, Inc., Scholar Rock, Inc., and Takeda Pharmaceutical Company Limited.

The report provides insights on the following pointers:

  1. Market Penetration: Provides comprehensive information on the market offered by the key players
  2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
  3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
  5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  1. What is the market size and forecast of the Global Spinal Muscular Atrophy Treatment Market?
  2. What are the inhibiting factors and impact of COVID-19 shaping the Global Spinal Muscular Atrophy Treatment Market during the forecast period?
  3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Spinal Muscular Atrophy Treatment Market?
  4. What is the competitive strategic window for opportunities in the Global Spinal Muscular Atrophy Treatment Market?
  5. What are the technology trends and regulatory frameworks in the Global Spinal Muscular Atrophy Treatment Market?
  6. What is the market share of the leading vendors in the Global Spinal Muscular Atrophy Treatment Market?
  7. What modes and strategic moves are considered suitable for entering the Global Spinal Muscular Atrophy Treatment Market?
Frequently Asked Questions about the Global Spinal Muscular Atrophy Treatment Market

What is the estimated value of the Global Spinal Muscular Atrophy Treatment Market?

The Global Spinal Muscular Atrophy Treatment Market was estimated to be valued at $1394.26 Million in 2022.

What is the growth rate of the Global Spinal Muscular Atrophy Treatment Market?

The growth rate of the Global Spinal Muscular Atrophy Treatment Market is 15.3%, with an estimated value of $4379.52 Million by 2030.

What is the forecasted size of the Global Spinal Muscular Atrophy Treatment Market?

The Global Spinal Muscular Atrophy Treatment Market is estimated to be worth $4379.52 Million by 2030.

Who are the key companies in the Global Spinal Muscular Atrophy Treatment Market?

Key companies in the Global Spinal Muscular Atrophy Treatment Market include Astellas Pharma Inc., Biogen Inc., Catalyst Pharmaceuticals, Inc., Cytokinetics, Incorporated, F. Hoffmann, La Roche Ltd., Ionis Pharmaceuticals, Inc., Natera Inc., NMD PHARMA A/S and Novartis AG.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Spinal Muscular Atrophy Treatment Market, by Type, 2022 vs 2030
4.3. Spinal Muscular Atrophy Treatment Market, by Treatment, 2022 vs 2030
4.4. Spinal Muscular Atrophy Treatment Market, by Route of Administration, 2022 vs 2030
4.5. Spinal Muscular Atrophy Treatment Market, by Region, 2022 vs 2030
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising burden of spinal muscular atrophy
5.1.1.2. Favorable reimbursements for spinal muscular atrophy treatment
5.1.1.3. Awareness programs initiatives by government and nonprofit organizations
5.1.2. Restraints
5.1.2.1. Limited time-window for successful therapy delivery
5.1.3. Opportunities
5.1.3.1. R&D for expanding possibilities of spinal muscular atrophy treatment efficacy
5.1.3.2. Expansion of online medication distribution channels
5.1.4. Challenges
5.1.4.1. Shortage of trained professionals
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization
6. Spinal Muscular Atrophy Treatment Market, by Type
6.1. Introduction
6.2. Type 1
6.3. Type 2
6.4. Type 3
6.5. Type 4
7. Spinal Muscular Atrophy Treatment Market, by Treatment
7.1. Introduction
7.2. Drug Therapy
7.3. Gene Replacement Therapy
8. Spinal Muscular Atrophy Treatment Market, by Route of Administration
8.1. Introduction
8.2. Intrathecal
8.3. Oral
9. Americas Spinal Muscular Atrophy Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Spinal Muscular Atrophy Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Spinal Muscular Atrophy Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
13. Company Usability Profiles
13.1. Astellas Pharma Inc.
13.2. Biogen Inc.
13.3. Catalyst Pharmaceuticals, Inc.
13.4. Cytokinetics, Incorporated
13.5. F. Hoffmann-La Roche Ltd.
13.6. Ionis Pharmaceuticals, Inc.
13.7. Natera Inc.
13.8. NMD PHARMA A/S
13.9. Novartis AG
13.10. Novo Nordisk A/S
13.11. PerkinElmer, Inc.
13.12. Pfizer Inc.
13.13. PTC Therapeutics, Inc.
13.14. Scholar Rock, Inc.
13.15. Takeda Pharmaceutical Company Limited
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2022 VS 2030
FIGURE 3. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 5. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
FIGURE 6. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
FIGURE 7. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 8. SPINAL MUSCULAR ATROPHY TREATMENT MARKET DYNAMICS
FIGURE 9. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 10. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 17. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 5. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 6. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 10. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 13. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 27. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 47. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 53. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 90. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 108. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 111. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 114. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 126. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 135. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, SCORES, 2022
TABLE 143. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, BUSINESS STRATEGY, 2022
TABLE 144. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, PRODUCT SATISFACTION, 2022
TABLE 145. SPINAL MUSCULAR ATROPHY TREATMENT MARKET RANKING, BY KEY PLAYER, 2022
TABLE 146. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
TABLE 147. SPINAL MUSCULAR ATROPHY TREATMENT MARKET LICENSE & PRICING

Companies Mentioned

  • Astellas Pharma Inc.
  • Biogen Inc.
  • Catalyst Pharmaceuticals, Inc.
  • Cytokinetics, Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Natera Inc.
  • NMD PHARMA A/S
  • Novartis AG
  • Novo Nordisk A/S
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Scholar Rock, Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...